The U.S. excels at funding discovery and celebrating breakthroughs, then neglects the hard work of manufacturing them at ...

"The conditions are perfect" for biotech's big annual party in San Francisco, an industry leader told the Business Times.

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

Our first biotech bi-weekly of 2026 is here with recent innovations in genomic drug discovery, organoid development and ADC ...

As they prepare for the J.P. Morgan Healthcare Conference next week, biotech leaders and analysts say companies are better ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a deal that may be worth $28 billion to $32 billion ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

Brisbane-based biotech company Vaxxas has appointed veteran pharmaceutical industry leader David Peacock as its new CEO as it moves to commercialise its needly free vaccination technology. Mr Peacock ...

A worldwide leader in injectable drug administration will be the newest company to set up shop in Greenfield, and anticipates ...